183 related articles for article (PubMed ID: 1698740)
1. Interleukin-1 abrogates anterior chamber-associated immune deviation.
Benson JL; Niederkorn JY
Invest Ophthalmol Vis Sci; 1990 Oct; 31(10):2123-8. PubMed ID: 1698740
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the suppressor cell(s) responsible for anterior chamber-associated immune deviation (ACAID) induced in BALB/c mice by P815 cells.
Streilein JW; Niederkorn JY
J Immunol; 1985 Mar; 134(3):1381-7. PubMed ID: 3155766
[TBL] [Abstract][Full Text] [Related]
3. Exogenous recombinant interleukin-2 abrogates anterior-chamber-associated immune deviation.
Niederkorn JY
Transplantation; 1987 Apr; 43(4):523-8. PubMed ID: 2953091
[TBL] [Abstract][Full Text] [Related]
4. Studies on the induction of anterior chamber-associated immune deviation (ACAID). II. Eye-derived cells participate in generating blood-borne signals that induce ACAID.
Wilbanks GA; Mammolenti M; Streilein JW
J Immunol; 1991 May; 146(9):3018-24. PubMed ID: 2016537
[TBL] [Abstract][Full Text] [Related]
5. Correlation of anterior chamber-associated immune deviation with suppression of corneal epithelial rejection in mice.
Yao YF; Inoue Y; Miyazaki D; Hara Y; Shimomura Y; Tano Y; Ohashi Y
Invest Ophthalmol Vis Sci; 1997 Feb; 38(2):292-300. PubMed ID: 9040461
[TBL] [Abstract][Full Text] [Related]
6. Immune privilege is extended, then withdrawn, from allogeneic tumor cell grafts placed in the subretinal space.
Wenkel H; Chen PW; Ksander BR; Streilein JW
Invest Ophthalmol Vis Sci; 1999 Dec; 40(13):3202-8. PubMed ID: 10586943
[TBL] [Abstract][Full Text] [Related]
7. Anterior chamber inoculation of splenocytes without Fas/Fas-ligand interaction primes for a delayed-type hypersensitivity response rather than inducing anterior chamber-associated immune deviation.
Kawashima H; Yamagami S; Tsuru T; Gregerson DS
Eur J Immunol; 1997 Oct; 27(10):2490-4. PubMed ID: 9368601
[TBL] [Abstract][Full Text] [Related]
8. Role of splenic B cells in the immune privilege of the anterior chamber of the eye.
Niederkorn JY; Mayhew E
Eur J Immunol; 1995 Oct; 25(10):2783-7. PubMed ID: 7589072
[TBL] [Abstract][Full Text] [Related]
9. Studies on the induction of anterior chamber-associated immune deviation (ACAID). 1. Evidence that an antigen-specific, ACAID-inducing, cell-associated signal exists in the peripheral blood.
Wilbanks GA; Streilein JW
J Immunol; 1991 Apr; 146(8):2610-7. PubMed ID: 1707912
[TBL] [Abstract][Full Text] [Related]
10. Induction of anterior chamber-associated immune deviation (ACAID) by allogeneic intraocular tumors does not require splenic metastases.
Niederkorn JY; Streilein JW
J Immunol; 1982 Jun; 128(6):2470-4. PubMed ID: 6804562
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-1 receptor antagonist therapy and induction of anterior chamber-associated immune deviation-type tolerance after corneal transplantation.
Yamada J; Zhu SN; Streilein JW; Dana MR
Invest Ophthalmol Vis Sci; 2000 Dec; 41(13):4203-8. PubMed ID: 11095616
[TBL] [Abstract][Full Text] [Related]
12. A novel role for TGF-beta and IL-10 in the induction of immune privilege.
D'Orazio TJ; Niederkorn JY
J Immunol; 1998 Mar; 160(5):2089-98. PubMed ID: 9498745
[TBL] [Abstract][Full Text] [Related]
13. The immune response and the eye: a role for TNF alpha in anterior chamber-associated immune deviation.
Ferguson TA; Herndon JM; Dube P
Invest Ophthalmol Vis Sci; 1994 Apr; 35(5):2643-51. PubMed ID: 8163352
[TBL] [Abstract][Full Text] [Related]
14. Requirement of CD80+ costimulation for rejection of ocular tumors and termination of immune privilege.
Chen PW; Uno T; Ksander BR
Exp Eye Res; 2006 Sep; 83(3):574-83. PubMed ID: 16643898
[TBL] [Abstract][Full Text] [Related]
15. Studies on the induction of anterior chamber-associated immune deviation (ACAID). III. Induction of ACAID depends upon intraocular transforming growth factor-beta.
Wilbanks GA; Mammolenti M; Streilein JW
Eur J Immunol; 1992 Jan; 22(1):165-73. PubMed ID: 1530916
[TBL] [Abstract][Full Text] [Related]
16. Lymphoma allografts abrogate immune privilege within the anterior chamber of the eye.
Niederkorn JY; Streilein JW
Invest Ophthalmol Vis Sci; 1986 Aug; 27(8):1235-43. PubMed ID: 3089965
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-1 receptor antagonist suppresses Langerhans cell activity and promotes ocular immune privilege.
Dana MR; Dai R; Zhu S; Yamada J; Streilein JW
Invest Ophthalmol Vis Sci; 1998 Jan; 39(1):70-7. PubMed ID: 9430547
[TBL] [Abstract][Full Text] [Related]
18. Implication for the CD94/NKG2A-Qa-1 system in the generation and function of ocular-induced splenic CD8+ regulatory T cells.
Chattopadhyay S; O'Rourke J; Cone RE
Int Immunol; 2008 Apr; 20(4):509-16. PubMed ID: 18359787
[TBL] [Abstract][Full Text] [Related]
19. Genetic restrictions and cellular interactions in the induction of anterior chamber associated immune deviation (ACAID).
Ferguson TA; Kaplan HJ
Reg Immunol; 1988; 1(1):62-8. PubMed ID: 2978943
[TBL] [Abstract][Full Text] [Related]
20. Induction of anterior chamber-associated immune deviation by corneal allografts placed in the anterior chamber.
Yamada J; Streilein JW
Invest Ophthalmol Vis Sci; 1997 Dec; 38(13):2833-43. PubMed ID: 9418737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
